2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Thyroid Neoplasms
12
Thyroid Cancer, Papillary
5
Adenocarcinoma, Follicular
5
Differentiated Thyroid Cancer
4
Recombinant Human Thyroid Stimulating Hormone
1
Neoplasm Metastasis
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Low Risk Differentiated Thyroid Cancer
1
Hypothyroidism
1
Heterotaxy Syndrome
1
Head and Neck Neoplasms
1
DTC - Differentiated Thyroid Cancer
1
Interventions
Cisplatin
258
Radiotherapy
193
Cetuximab
151
pembrolizumab
123
Docetaxel
97
Fluorouracil
92
Carboplatin
80
Paclitaxel
78
Radiotherapy, Intensity-Modulated
72
Surveys and Questionnaires
46
Nivolumab
42
Drug Therapy
34
Radiation
33
Blood Specimen Collection
27
Erlotinib Hydrochloride
26
Gemcitabine
25
Immunohistochemistry
22
Gefitinib
22
Cyclophosphamide
22
Surgical Procedures, Operative
21
Standard of Care
20
durvalumab
19
Pemetrexed
19
Magnetic Resonance Spectroscopy
19
Radiosurgery
17
Capecitabine
17
Chemotherapy, Adjuvant
16
Celecoxib
16
Biopsy
16
atezolizumab
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Thyrotropin Alfa
×
Clear all
NCT00415233
2023-12-19
HiLo
University College, London
Phase 3
Unknown
438 enrolled